Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.45 USD -2.03% Intraday chart for Corvus Pharmaceuticals, Inc. +3.57% -17.61%
Apr. 09 Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CI
Mar. 20 Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT

Evolution of the average Target Price on Corvus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e07eb35c332e6ca14.sCWuck6ZqujAw-_O9WEEZcXg7FG0iXTNFZjXmo9PPKs.-3rYSxvMxp6YpoL4hytvCuiUviiG0S6eJq-6w8p8WPPZcd0eKdDFsK-giA~1fcd1427eeaaf14236cfdc5cccc2068f

Analyst Recommendations on Corvus Pharmaceuticals, Inc.

Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target MT
Ladenburg Thalmann Adjusts Corvus Pharmaceuticals Price Target to $10 From $4, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating MT
Ladenburg Thalmann Starts Corvus Pharmaceuticals at Buy with $2 Price Target MT
Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $8 From $5, Maintains Overweight Rating MT
Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating MT
CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to $3.50 From $4, Maintains Neutral Rating MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Starts Corvus Pharmaceuticals With Overweight Rating, $10 Price Target MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Corvus Pharmaceuticals to $9.50 From $12, Maintains Buy Rating MT
CORVUS PHARMACEUTICALS : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7 MT
CORVUS PHARMACEUTICALS : Wedbush Adjusts Price Target on Corvus Pharmaceuticals to $6 From $8, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.45 USD
Average target price
7.5 USD
Spread / Average Target
+417.24%
High Price Target
12 USD
Spread / Highest target
+727.59%
Low Price Target
3.5 USD
Spread / Lowest Target
+141.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corvus Pharmaceuticals, Inc.

Oppenheimer
Ladenburg Thalmann
Cantor Fitzgerald
Jefferies & Co.
Mizuho Securities
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. Consensus Corvus Pharmaceuticals, Inc.